Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Market Cap	$5.74B	P/E Ratio	32.58
52W High	$298.30	52W Low	$122.80
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	44.2%	52W Position	77.2%
Overall Score	63	Value Score	60
Quality Score	50	Technical Score	81

EPS Current Est	$7.93	EPS Next Est	$12.9
EPS Growth Est	+62.7%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KRYS	$258.33	-2.23%	228.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KRYS	$258.33	-2.2%	228.21K
3
4
5
6

KRYS

KRYS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Krystal Biotech Inc. Data in Excel

Get Krystal Biotech Inc. Data in Excel